Compounds > 3-iodobenzylguanidine
Page last updated: 2024-08-24

3-iodobenzylguanidine and Peritoneal Neoplasms

3-iodobenzylguanidine has been researched along with Peritoneal Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Bal, CS; Dadhwal, R; Jain, S; Seth, A1
Cheng, J; Ou, X; Wang, H1
Buteau, FA; Makis, W; McCann, K; McEwan, AJ1
Bunko, H; Kinuya, S; Li, XF; Michigishi, T; Mori, H; Shiba, K; Shuke, N; Tonami, N; Watanabe, N; Yokoyama, K1
Kline, G; McEwan, A; Pasieka, JL; Rorstad, O; Sywak, MS1
Crasset, V; Dekoninck, W; Delcourt, E1

Other Studies

6 other study(ies) available for 3-iodobenzylguanidine and Peritoneal Neoplasms

ArticleYear
Neuroendocrine tumour of urinary bladder: a rare case of aggressively behaving primary well-differentiated neuroendocrine tumour with review of literature.
    BMJ case reports, 2019, Nov-19, Volume: 12, Issue:11

    Topics: 3-Iodobenzylguanidine; Administration, Intravenous; Adult; Cell Differentiation; Diagnosis, Differential; Enzyme Inhibitors; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Neuroendocrine Tumors; Peritoneal Neoplasms; Treatment Outcome; Urinary Bladder

2019
Recurrent Malignant Pheochromocytoma With Unusual Peritoneal Carcinomatosis Detected on 131I-MIBG SPECT/CT.
    Clinical nuclear medicine, 2021, Volume: 46, Issue:1

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Female; Humans; Male; Middle Aged; Peritoneal Neoplasms; Pheochromocytoma; Recurrence; Single Photon Emission Computed Tomography Computed Tomography

2021
Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:7

    Topics: 3-Iodobenzylguanidine; Adult; Antineoplastic Agents; Ascites; Bone Neoplasms; Disease Progression; Humans; Intestinal Neoplasms; Liver Neoplasms; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peritoneal Neoplasms; Radiopharmaceuticals

2015
Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:9

    Topics: 3-Iodobenzylguanidine; Animals; Body Burden; Dose-Response Relationship, Radiation; Female; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neuroblastoma; Organ Specificity; Peritoneal Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Survival Rate; Tissue Distribution; Treatment Outcome; Whole-Body Counting

2003
131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
    World journal of surgery, 2004, Volume: 28, Issue:11

    Topics: 3-Iodobenzylguanidine; Aged; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Female; Humans; Ileal Neoplasms; Intestinal Neoplasms; Jejunal Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis

2004
Detection of a carcinoid tumor by the radionuclide method.
    Clinical nuclear medicine, 1994, Volume: 19, Issue:10

    Topics: 3-Iodobenzylguanidine; Carcinoid Tumor; Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Iodobenzenes; Middle Aged; Octreotide; Peritoneal Neoplasms; Radionuclide Imaging; Sensitivity and Specificity

1994